Table 1.
Patient characteristics
| Characteristic | 200 mg bid (n = 13) | 400 mg bid (n = 14) | Total (n = 27) |
|---|---|---|---|
| Sex (n) | |||
| Male | 12 | 13 | 25 |
| Female | 1 | 1 | 2 |
| Median age (years) | 69 (range 48–77) | 70 (range 63–79) | 70 (range 48–79) |
| Eastern Cooperative Oncology Group performance status | |||
| 0 | 13 | 14 | 27 |
| Child–Pugh classification | |||
| A | 7 | 6 | 13 |
| B | 6 | 8 | 14 |
| Viral markers | |||
| HB antigen+, HCV antibody− | 3 | 1 | 4 |
| HB antigen−, HCV antibody+ | 9 | 11 | 20 |
| HB antigen−, HCV antibody− | 1 | 2 | 3 |
| Previous treatment | |||
| – | 1 | 3 | 4 |
| + | 12 | 11 | 23 |
| Tumor stage | |||
| II | 1 | 2 | 3 |
| III | 7 | 8 | 15 |
| IVa | 1 | 1 | 2 |
| IVb | 4 | 3 | 7 |
| Portal vein tumor thrombus | |||
| – | 12 | 13 | 25 |
| + | 1 | 1 | 2 |
| Metastasis | |||
| – | 9 | 11 | 20 |
| + | 4 | 3 | 7 |
| Lung | 3 | 1 | 4 |
| Lung + lymph node | 1 | 1 | 2 |
| Lymph node | 0 | 1 | 1 |
HB, hepatitis B; HCV, hepatitis C virus.